Question 1

How do I safely taper an SSRI, and what withdrawal symptoms should I warn about?

Accepted Answer

The 2024 Lancet Psychiatry meta-analysis (79 studies, 21,002 patients; Henssler et al., 2024) estimates ~15% of patients experience genuine discontinuation symptoms after subtracting nocebo effects, with ~1 in 35 experiencing severe symptoms. Risk varies by agent: desvenlafaxine/venlafaxine highest (IR=0.40), sertraline intermediate (IR=0.18), fluoxetine lowest (IR=0.15). Standard taper: 25-50% reduction every 2-4 weeks. For patients who failed linear tapering, hyperbolic tapering achieved 72% successful discontinuation (Horowitz & Taylor, 2019, Lancet Psychiatry; Groot & van Os, 2021). Discontinuation is pharmacologically distinct from relapse: onset within days (vs weeks), presence of neurological symptoms (brain zaps, paresthesias), rapid resolution upon reinstating. Minimum 12 months remission before attempting taper.

Question 2

What is SSRI discontinuation syndrome and how common is it?

Accepted Answer

The 2024 Lancet Psychiatry meta-analysis (79 studies, 21,002 patients; Henssler et al., 2024) estimates ~15% of patients experience genuine discontinuation symptoms after subtracting nocebo effects, with ~1 in 35 experiencing severe symptoms. Risk varies by agent: desvenlafaxine/venlafaxine highest (IR=0.40), sertraline intermediate (IR=0.18), fluoxetine lowest (IR=0.15). Standard taper: 25-50% reduction every 2-4 weeks. For patients who failed linear tapering, hyperbolic tapering achieved 72% successful discontinuation (Horowitz & Taylor, 2019, Lancet Psychiatry; Groot & van Os, 2021). Discontinuation is pharmacologically distinct from relapse: onset within days (vs weeks), presence of neurological symptoms (brain zaps, paresthesias), rapid resolution upon reinstating. Minimum 12 months remission before attempting taper.

Question 3

Which SSRIs have the highest discontinuation risk (paroxetine, venlafaxine)?

Accepted Answer

The 2024 Lancet Psychiatry meta-analysis (79 studies, 21,002 patients; Henssler et al., 2024) estimates ~15% of patients experience genuine discontinuation symptoms after subtracting nocebo effects, with ~1 in 35 experiencing severe symptoms. Risk varies by agent: desvenlafaxine/venlafaxine highest (IR=0.40), sertraline intermediate (IR=0.18), fluoxetine lowest (IR=0.15). Standard taper: 25-50% reduction every 2-4 weeks. For patients who failed linear tapering, hyperbolic tapering achieved 72% successful discontinuation (Horowitz & Taylor, 2019, Lancet Psychiatry; Groot & van Os, 2021). Discontinuation is pharmacologically distinct from relapse: onset within days (vs weeks), presence of neurological symptoms (brain zaps, paresthesias), rapid resolution upon reinstating. Minimum 12 months remission before attempting taper.

Question 4

What's the recommended taper schedule?

Accepted Answer

The 2024 Lancet Psychiatry meta-analysis (79 studies, 21,002 patients; Henssler et al., 2024) estimates ~15% of patients experience genuine discontinuation symptoms after subtracting nocebo effects, with ~1 in 35 experiencing severe symptoms. Risk varies by agent: desvenlafaxine/venlafaxine highest (IR=0.40), sertraline intermediate (IR=0.18), fluoxetine lowest (IR=0.15). Standard taper: 25-50% reduction every 2-4 weeks. For patients who failed linear tapering, hyperbolic tapering achieved 72% successful discontinuation (Horowitz & Taylor, 2019, Lancet Psychiatry; Groot & van Os, 2021). Discontinuation is pharmacologically distinct from relapse: onset within days (vs weeks), presence of neurological symptoms (brain zaps, paresthesias), rapid resolution upon reinstating. Minimum 12 months remission before attempting taper.

Question 5

How do I distinguish discontinuation symptoms from anxiety relapse?

Accepted Answer

The 2024 Lancet Psychiatry meta-analysis (79 studies, 21,002 patients; Henssler et al., 2024) estimates ~15% of patients experience genuine discontinuation symptoms after subtracting nocebo effects, with ~1 in 35 experiencing severe symptoms. Risk varies by agent: desvenlafaxine/venlafaxine highest (IR=0.40), sertraline intermediate (IR=0.18), fluoxetine lowest (IR=0.15). Standard taper: 25-50% reduction every 2-4 weeks. For patients who failed linear tapering, hyperbolic tapering achieved 72% successful discontinuation (Horowitz & Taylor, 2019, Lancet Psychiatry; Groot & van Os, 2021). Discontinuation is pharmacologically distinct from relapse: onset within days (vs weeks), presence of neurological symptoms (brain zaps, paresthesias), rapid resolution upon reinstating. Minimum 12 months remission before attempting taper.

PsychHQ

SSRI Discontinuation Syndrome: When Stopping Becomes Symptomatic